Heat Biologics (“NightHawk Biosciences”) Completes Acquisition of Elusys Therapeutics

Provided By Globe Newswire

Last update: Apr 20, 2022

Elusys becomes wholly-owned biodefense subsidiary of NightHawk

Plans to expand ANTHIM® distribution abroad

DURHAM, N.C., April 20, 2022 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (NYSE American: HTBX) (to be renamed “NightHawk Biosciences”), a fully-integrated biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, today announced it has completed the acquisition of Elusys Therapeutics, Inc. a commercial-stage biodefense company and developer of ANTHIM® (obiltoxaximab), a treatment for inhalation anthrax. ANTHIM® is approved for use in the U.S. and Canada, and under the brand name Obiltoxaximab SFL in Europe and the United Kingdom.